By Ian Walker

Volex, the London-listed power and data-cabling company, announced that its first-half revenue has risen by 4% due to its successful diversification strategy. The company also stated that it anticipates meeting full-year market forecasts.

Following a recent cyberattack, Volex reassured customers that all of its sites are fully operational and production is back to normal. The cyberattack caused minimal disruption to customers and is not expected to have a significant impact on revenue or underlying operating profit. However, the company does anticipate booking costs of $2 million in the second half of the year.

For the year ending March 31, Volex has provided a revenue forecast in the range of $849.8 million to $891.0 million, with a consensus estimate of $864.6 million. The underlying operating profit forecast falls between $82.3 million and $87.0 million, with a consensus estimate of $84.3 million.

Despite the cyberattack, Volex's board remains optimistic about several potential near-term sales opportunities in the second half of the year. The company remains on track to deliver full-year results in line with market expectations.

At 0808 GMT, Volex shares were up by 3.50 pence or 1.25%, reaching 284.50 pence.

Investor Concerns Over Slowing Demand and Weight Loss Drugs Cloud Coca-Cola's Solid Earnings Quarter

Spotify Reports Strong Financial Performance

Leave A Reply

Your email address will not be published. Required fields are marked *

Related posts

A Multi-Billion Dollar Jackpot Awaits
News

A Multi-Billion Dollar Jackpot Awaits

The upcoming Mega Millions lottery drawing presents an opportunity for players across 45 states and Washington, D.C. to...

The Dangers of Picking Mutual Funds Based on Style Category
News

The Dangers of Picking Mutual Funds Based on Style Category

Investors often make the mistake of selecting mutual funds based solely on style category, but this approach can lead to...

O-I Glass Reports Loss in Q4
News

O-I Glass Reports Loss in Q4

O-I Glass reports a loss of $470 million in Q4 due to goodwill impairment charge and lower sales volumes. However, the c...

Replimune Faces Setback in Skin Cancer Trial
News

Replimune Faces Setback in Skin Cancer Trial

Replimune Group Inc. experienced a setback in a skin cancer trial, leading to a decline in shares. The trial results wer...